The design and preclinical testing of Ad5FGF-4 to treat chronic myocardial ischaemia

European Heart Journal, Supplement

Volumn 6, Issue E, 2004, Pages

  Rubanyi, G M ^a  

^a BAYER AG   (Germany)

Author keywords

Adenovirus; Angiogenesis; Collateral coronary arteries; Fibroblast growth factor; Myocardial ischaemia; Stable angina

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; BETA GALACTOSIDASE; DRUG CARRIER; EPHRIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 8; LENTIVIRUS VECTOR; LIPOSOME; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACENTAL GROWTH FACTOR; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RETROVIRUS VECTOR; SCATTER FACTOR; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; BACULOVIRUS EXPRESSION SYSTEM; BLOOD FLOW; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ANOMALY; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY OBSTRUCTION; DEATH; DRUG DESIGN; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HERPES SIMPLEX VIRUS; HUMAN; HYPOTENSION; INTRACORONARY INFUSION; LEUKOCYTOSIS; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; SENDAI VIRUS; TACHYCARDIA;

EID: 4043136596     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.06.004     Document Type: Conference Paper

References (24)

1. Wustmann K., Zbinden S., Windecker S., et al. Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation. 107:2003;2213-2220
2. Hansen J.F. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am. Heart J. 117:1989;290-295
3. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9:2003;653-660
4. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9:2003;677-684
5. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9:2003;685-693
6. Ylä-Herttuala S., Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. 9:2003;694-701
7. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9:2003;669-676
8. Deindl E., Fernández B., Höfer I.E., et al. Arteriogenesis, collateral blood vessels, and their development. Rubanyi G.M. Angiogenesis in health and disease. 2000;31-45 Marcel Dekker, New York
9. House S.L., Bolte C., Zhou M., et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation. 108:2003;3140-3148
10. Khurana R., Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc. Med. 13:2003;116-122
11. Bush M.A., Samara E., Whitehouse M.J., et al. Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J. Clin. Pharmacol. 41:2001;378-385
12. Simons M., Annex B.H., Laham R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 105:2002;788-793
13. Ruel M., Laham R.J., Parker J.A., et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 124:2002;28-34
14. Rubanyi G.M. The future of human gene therapy. Mol. Aspects Med. 22:2001;113-142
15. Losordo D.W., Vale P.R., Hendel R.C., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 105:2002;2012-2018
16. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 105:2002;1291-1297
17. Hedman M., Hartikainen J., Syvanne M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 107:2003;2677-2683
18. Boekstegers P. Perspectives on selective retroinfusion of coronary veins as an alternative approach for myocardial gene transfer and angiogenesis. J. Invasive Cardiol. 13:2001;339-342
19. Giordano F.J., Ping P., McKirnan M.D., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2:1996;534-539
20. Roth D.M., Maruoka Y., Rogers J., et al. Development of coronary collateral circulation in left circumflex Ameroid-occluded swine myocardium. Am. J. Physiol. 253:1987;H1279-H1288
21. Gao M.H., Lai C.N., McKirnan M.D., et al. Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor-4: report of preclinical data. Hum Gene Ther. 15:2004;574-587
22. Peters A.H., Drumm J., Ferrell C., et al. Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol. Ther. 4:2001;603-613
23. Watkins M.W., Rubanyi G.M. Gene therapy for coronary artery disease: preclinical and initial clinical results with intracoronary administration of Ad5FGF-4. Rubanyi G.M., Ylä-Herttuala S. Human gene therapy: current opportunities and future trends. 2003;61-78 Springer, Berlin
24. Rissanen T.T., Markkanen J.E., Arve K., et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 17:2003;100-112